March 9, 2013
nov·el & ex·cit·ing $PVCT
The following comes from my due diligence, and not from Provectus management. A senior executive at a Big Pharma company, a counterpart of Pfizer's Dr. Eagle, believes it is rare to see a novel and exciting new compound or drug candidate come along in this industry. PV-10 has the potential to be that one new and exciting drug. There is an elevated level of excitement surrounding PV-10 in the pharmaceutical community and with that comes an elevated level of scrutiny as is to be expected with a novel compound that is producing such profound results.